Bristol-Myers Squibb Company (BMY) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Total Assets Chart for Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) total assets for FY2025 were USD 90.0B, a -2.8% change from FY2024. Bristol-Myers Squibb Company's total assets grew from USD 7.5B in 1987 to USD 90.0B in 2025 (1098.3% over 38 years). Total assets compound annual growth rate: 5-year CAGR of -5.3%, 10-year CAGR of 11.0%, 20-year CAGR of 6.0%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $131.04B
- Implied Share Price
- $64.15
- Enterprise Value
- $167.40B
- Revenue (TTM)
- $49.19B
- EBITDA
- $18.93B
- Profit Margin
- 18.87%
- Trailing P/E
- 14.13
- Forward P/E
- 10.33
- Price/Book (MRQ)
- 5.98
- Price/Sales (TTM)
- 2.66
- EV/EBITDA
- 9.95
- EV/Revenue
- 3.40
- Dividend Yield
- 3.94%
- Book Value
- $10.93
- Free Cash Flow (FY2025)
- $12.85B
- Free Cash Flow Yield
- 9.80%
Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.